Lp(a): The Inherited Risk Factor
You Need to Know About

This section provides detailed scientific context for researchers, clinicians, and health enthusiasts who want to understand the full evidence base for Lp(a) as a cardiovascular risk factor.

Molecular Structure and Genetics

Lipoprotein(a) consists of an LDL-like particle with apolipoprotein B-100 (ApoB-100) covalently linked via a single disulfide bond to apolipoprotein(a), or apo(a). The apo(a) protein is encoded by the LPA gene on chromosome 6q26-27 and shows remarkable structural homology to plasminogen, the precursor of the fibrinolytic enzyme plasmin.

Apo(a) contains multiple repeating structures called kringles. The number of kringle IV type 2 (KIV-2) repeats is highly variable (from 3 to >40 copies) and inversely correlates with Lp(a) concentration: smaller apo(a) isoforms (fewer kringles) are associated with higher Lp(a) levels. This copy number variation is the primary determinant of Lp(a) levels and explains the wide inter-individual variation (from <1 to >200 nmol/L).

Lp(a) levels are approximately 90% heritable, making it one of the most genetically determined cardiovascular risk factors known. Levels are established by age 2 and remain relatively stable throughout life, unaffected by diet, exercise, or most lipid-lowering medications. This genetic determination is why a single lifetime measurement is sufficient for risk assessment.

Causal Evidence from Mendelian Randomization

The causal relationship between Lp(a) and cardiovascular disease has been established through multiple Mendelian randomization studies. Because LPA gene variants that affect Lp(a) levels are randomly assigned at conception, they act as natural experiments free from confounding.

The Copenhagen City Heart Study and Copenhagen General Population Study, analyzing over 100,000 individuals, found that genetic variants associated with higher Lp(a) predicted increased risk of myocardial infarction independent of LDL-C. Specifically, individuals with the highest genetically predicted Lp(a) levels had 2-3 fold higher MI risk compared to those with the lowest levels.

Quantitatively, Mendelian randomization analyses suggest that a genetically determined doubling of Lp(a) concentration increases MI risk by approximately 22%. On an equimolar basis, Lp(a) appears to be approximately 5-6 times more atherogenic than LDL, likely due to its additional prothrombotic and pro-inflammatory properties.

Oxidized Phospholipids: The Inflammatory Payload

One of the most important discoveries about Lp(a) pathophysiology is its role as the preferential carrier of oxidized phospholipids (OxPL) in human plasma. Tsimikas and colleagues demonstrated that approximately 85% of OxPL precipitated by anti-ApoB antibodies associate with Lp(a) particles.

OxPL are potent pro-inflammatory molecules that activate innate immune pathways via pattern recognition receptors (particularly TLR2 and CD36). When Lp(a) deposits in the arterial wall, it delivers a concentrated payload of OxPL that promotes monocyte chemotaxis, macrophage activation, and foam cell formation.

Van der Valk et al. (Circulation 2016) performed arterial wall PET imaging in subjects with elevated Lp(a) and demonstrated increased arterial inflammation and enhanced monocyte trafficking to the vessel wall. Critically, these inflammatory effects were substantially attenuated when OxPL on Lp(a) were inactivated, establishing OxPL as a key mediator of Lp(a)-driven inflammation.

This "dual mechanism" explains why Lp(a) is so dangerous: it provides both the cholesterol substrate for plaque formation (like LDL) and simultaneously delivers inflammatory triggers that accelerate the disease process. Some researchers describe this as Lp(a) being both the "fuel" and the "arsonist."

Prothrombotic Effects

The structural homology between apo(a) and plasminogen has functional consequences. Apo(a) competes with plasminogen for binding to fibrin and cell surfaces, effectively inhibiting plasmin generation and fibrinolysis. This creates a prothrombotic state that increases the risk of clot propagation after plaque rupture.

This mechanism may explain why elevated Lp(a) is particularly associated with thrombotic complications of atherosclerosis (MI, stroke) rather than just plaque burden per se. It also provides a potential explanation for associations between Lp(a) and venous thromboembolism, though this relationship is less well established than for arterial disease.

Aortic Valve Calcification

Beyond coronary and cerebrovascular disease, Lp(a) is causally implicated in calcific aortic valve disease (CAVD). Mendelian randomization studies using LPA variants demonstrate a causal relationship between elevated Lp(a) and aortic stenosis, independent of coronary artery disease.

The mechanism appears related to OxPL-mediated inflammation of valve tissue and activation of osteogenic pathways. This has important clinical implications: patients with elevated Lp(a) should undergo periodic echocardiographic surveillance for valve disease, and Lp(a)-lowering therapies may have valve-protective effects beyond cardiovascular benefit.

Population Distribution and Ethnic Variation

Lp(a) levels show substantial ethnic variation. African-ancestry populations have 2-3 fold higher median Lp(a) levels compared to European-ancestry populations, with approximately 50% of Black individuals exceeding the 75 nmol/L threshold versus ~25% of White individuals.

Importantly, the relationship between Lp(a) and cardiovascular risk appears consistent across ethnic groups—elevated Lp(a) increases risk regardless of ancestry. However, the higher prevalence of elevated Lp(a) in Black populations may contribute to cardiovascular health disparities and underscores the importance of universal screening.

Current and Emerging Therapies

PCSK9 inhibitors (evolocumab, alirocumab) lower Lp(a) by approximately 20-30%, likely by increasing hepatic clearance of Lp(a) particles via upregulated LDL receptors. While not approved specifically for Lp(a), this effect provides additional benefit in patients with elevated Lp(a) who have indications for PCSK9i therapy.

Antisense oligonucleotides (ASOs) targeting hepatic apo(a) mRNA represent a more specific approach. Pelacarsen, developed by Novartis/Ionis, reduces Lp(a) by approximately 80% with monthly subcutaneous injections. The phase 3 HORIZON trial (n=8,323) is evaluating cardiovascular outcomes and is expected to report in 2025-2026.

Small interfering RNA (siRNA) therapies offer even more potent and durable Lp(a) lowering. Olpasiran (Amgen) achieves ~95% Lp(a) reduction with quarterly dosing. The phase 3 OCEAN(a)-Outcomes trial is ongoing. Other siRNA candidates (SLN360, lepodisiran) show similar efficacy in phase 2 studies.

The critical unanswered question is whether lowering Lp(a) translates to reduced cardiovascular events. Mendelian randomization predicts it should—estimates suggest ~20% risk reduction per 50 nmol/L Lp(a) lowering—but only outcomes trials can confirm this.

Lipoprotein Apheresis

For patients with very high Lp(a) (typically >200 nmol/L) and progressive cardiovascular disease despite maximal medical therapy, lipoprotein apheresis is available in some countries (particularly Germany). This procedure physically removes ApoB-containing particles (including Lp(a)) from plasma, achieving acute reductions of 60-75%.

Apheresis is performed every 1-2 weeks and is associated with reduced cardiovascular events in observational studies. However, it is invasive, expensive, and not widely available. It remains a niche therapy for the most severely affected patients while awaiting pharmacological alternatives.